COVID-19 has put the biopharma industry into a tailspin – big pharma, biotech and small startups are all emerging in the development of a treatment and vaccine for this pandemic. Will COVID-19 change the current R&D landscape and create a new norm for the biopharma industry?
In early March 2020, Seattle was considered to be a “hot spot” for the COVID-19 epidemic in the United States. A month later, Washington was one of the first states to have demonstrated success at “flattening the curve”. This presentation will explore important lessons learned that might be of value to other jurisdictions and what challenges we still face as we transition into the “post peak” phase of the epidemic in the Puget Sound.
Harsha Rajasimha, MS, PhD, Founder, Jeeva Informatics Solutions, Inc.; Founder and Chairman, IndoUSrare; Co-Director, Rare Diseases Systems Biology Initiative, George Mason University After losing a child to a rare congenital disease, Dr. Rajasimha became determined to apply his clinical genomics data research experience to develop solutions to help accelerate clinical research leading to faster cures for rare disease.
Over the past twenty years, the world has faced several infectious disease outbreaks including; Ebola, Influenza A (H1N1), SARS, MERS, Zika virus and now COVID-19. With over 200k deaths worldwide, COVID-19 has brought an enormous strain on our health resources, but also has had a massive impact on human health and the economy.
Edith Pfister, Ph.D., Assistant Professor, University of Massachusetts Medical This talk will cover the basics of therapies designed to lower huntingtin: what do we know and what don’t we know. It will introduce the basic mechanisms of huntingtin lowering and gene therapy.
Lindsey Riley, MPH, Senior Associate Director, Research Partnerships, The Michael J. Fox Foundation for Parkinson’s Research Patient reported outcomes (PRO) data complements traditional clinical research with scale & accessibility, as well as patient-centricity. The Fox Insight (FI) study aims to gather the world’s largest dataset on the day-to-day experience of living with PD, from 125,00 participants across the globe.